Addex amends at-the-market offering agreement with H.C. Wainwright

Addex Therapeutics (NASDAQ: ADXN) amended its at-the-market offering agreement with H.C. Wainwright & Co., the company announced. The agreement, originally entered into on January 30, 2024, allows Addex to sell American Depositary Shares worth up to $3.3 million through H.C. Wainwright as its sales agent.

Under the amended agreement, H.C. Wainwright may sell the ADSs through The Nasdaq Capital Market or other existing trading markets for the securities. The sales will be conducted as an "at-the-market offering" as defined under Securities Act Rule 415(a)(4), with H.C. Wainwright using commercially reasonable efforts to sell shares based on Addex's instructions.

Addex will pay H.C. Wainwright a sales commission of 3% of gross sales proceeds for any ADSs sold under the agreement. The company has also provided the sales agent with customary indemnification and contribution rights.

The company is not obligated to make any sales under the agreement. Both Addex and H.C. Wainwright may suspend or terminate the offering upon notice to the other party, subject to specified conditions.

Sales under the agreement will be made pursuant to Addex's effective registration statement on Form F-3, Registration Statement No. 333-291644. No securities sales are being made under the agreement in Switzerland.

Addex Therapeutics is a clinical-stage biopharmaceutical company developing small molecule allosteric modulators for neurological disorders. The company's shares trade on the SIX Swiss Exchange and its American Depositary Shares are listed on the NASDAQ Capital Market under the ticker "ADXN."

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Waymo wins California approval to expand ride-hailing service
• AI/ML Innovations plans $2M private placement on the CSE